Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial

Investigational New Drugs
Akira NakaoMasaki Fujita

Abstract

Background A global multicenter study demonstrated superiority of carboplatin + nab-paclitaxel (PTX) therapy compared to carboplatin + PTX in terms of response rate (RR) and non-inferiority in terms of progression free survival (PFS) and overall survival (OS) in untreated patients with stage IIIB/IV non-small cell lung cancer; no clinical findings have so far been reported on maintenance therapies with nab-PTX. The aim of this study was to determine the efficacy and safety of maintenance therapy with nab-PTX following carboplatin + nab-PTX combination therapy. Methods Carboplatin (AUC 6) was administered on Day 1; and nab-PTX 100 mg/m2 on Days 1, 8, and 15, and dosing was repeated in 4 courses of 4 weeks each. In patients with clinical response was observed at the end of the 4th course, nab-PTX maintenance therapy was repeated. Results Out of 39 patients included in the efficacy analysis, 19 (48.7%) patients completed the induction therapy and 15 (38.5%) were transitioned to maintenance therapy. The median PFS in the maintenance phase was 6.5 (90%CI 1.4-11.4) months. The median OS in 15 patients was 12.6 (95%CI: 7.4-not reached). Grade ≥ 3 toxicities observed in more than 5% of patients were neutropenia (55.0%), anemia (15.0%),...Continue Reading

References

Jan 11, 2002·The New England Journal of Medicine·Joan H SchillerUNKNOWN Eastern Cooperative Oncology Group
Jul 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chandra P BelaniGlenn M Mills
Apr 7, 2005·Journal of the National Cancer Institute·Virginie WesteelUNKNOWN French Thoracic Oncology Collaborative Group (GCOT)
Mar 30, 2006·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Thomas BrodowiczUNKNOWN Central European Cooperative Oncology Group CECOG
Dec 15, 2006·The New England Journal of Medicine·Alan SandlerDavid H Johnson
Jan 2, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Hisao AsamuraUNKNOWN Japanese Joint Committee of Lung Cancer Registry
Aug 6, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN NSCLC Meta-Analyses Collaborative Group
Dec 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Panos M FidiasJoan H Schiller
Apr 3, 2013·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Miyako SatouchiShunichi Negoro
Jan 10, 2018·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.